Smart Drugs for Her2 and Hodgkin’s


Thanks Google Image for diagram

About one in five cases of breast cancer are Her2 positive—meaning the tumors are high in protein. Great news! Not only for those with Her2, but for those with Hodgkin’s lymphoma.

The Food and Drug Administration has approved T-DM1. Usually women with Her2 breast cancer are given Herceptin, a monoclonal antibody that attaches to proteins on some cancer cells and slows or stops the growth of the cells. (http://www.cancer.gov/dictionary) along with a type of chemo. In the trials, the two drugs were attached to each other. The chemo remains inactive until the Herceptin carries it to the tumor. Side effects reported are temporary nausea, and some muscle cramps. T-DM1 is expected to be on market next year. http://www.utsandiego.com/news/2012/jun/20/tp-new-arsenal-in-cancer-war.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s